Tech and Drugs - Podcast

"From Molecules to Machine Learning: How AI Is Transforming Drug Discovery" Frédéric Célerse, PhD Shares Insights ⚖️💊 - Tech and Drugs - Podcast - Season 1 Episode 7 is now LIVE! In this episode, we dive into the wild world of quantum chemistry, AI models, and the science of speeding up science, with Frédéric Célerse, researcher, trailblazer, and passionate advocate for data-first innovation in drug discovery. We explore: ✅ Why Frédéric prefers “augmented” over “artificial” intelligence ✅ How machine learning is turbocharging molecular dynamics and quantum modeling ✅ What AI can (and cannot) do without human intuition ✅ The (very real) tensions between AI and wet-lab scientists, and how to build better bridges ✅ The hidden hero of innovation: data governance ✅ Why current publishing models need a reality check (yes, we’re side-eyeing traditional journals) ✅ What advice Frédéric has for students and future disruptors of the AI x Pharma space With AI accelerating drug discovery from months to days, this conversation is a must-listen for anyone working at the intersection of data, chemistry, and biology. Whether you’re coding models or pipetting proteins, there’s something in this episode for you. 💬 Curious about the role of AI in science? Got a take on quantum-to-clinic workflows? Drop your thoughts below, we love a good debate! 📌 Prefer video? Watch on YouTube https://lnkd.in/eiXU-nJz 📌 On the go? Listen on Spotify: https://lnkd.in/em-bDrUb or Apple Podcasts: https://lnkd.in/eGVAUGBV ________ 💡 Like what you hear? Subscribe to the podcast, leave a review, and follow us for more honest conversations at the frontier of tech and drugs.

Am I missing anything?

📅 Mark your calendar! – Tech and Drugs - Podcast – Season 1 Episode 7 drops on Tuesday April 8, 2025, at 11:30 CET, Join our guest, Frédéric Célerse, PhD, as we go from molecules to machine learning 🎙️ Here’s a teaser to spark your curiosity 👇 Theme: From Molecules to Machine Learning – How AI Is Transforming Drug Discovery In this episode, we dive into the wild world of quantum chemistry, AI models, and the science of speeding up science, with Frédéric Célerse, researcher, trailblazer, and passionate advocate for data-first innovation in drug discovery. We explore: ✅ Why Frédéric prefers “augmented” over “artificial” intelligence ✅ How machine learning is turbocharging molecular dynamics and quantum modeling ✅ What AI can (and cannot) do without human intuition ✅ The (very real) tensions between AI and wet-lab scientists, and how to build better bridges ✅ The hidden hero of innovation: data governance ✅ Why current publishing models need a reality check (yes, we’re side-eyeing traditional journals) ✅ What advice Frédéric has for students and future disruptors of the AI x Pharma space With AI accelerating drug discovery from months to days, this conversation is a must-listen for anyone working at the intersection of data, chemistry, and biology. Whether you’re coding models or pipetting proteins, there’s something in this episode for you. 💬 Curious about the role of AI in science? Got a take on quantum-to-clinic workflows? Drop your thoughts below, we love a good debate! ________ 💡 Like what you hear? Subscribe to the podcast, leave a review, and follow us for more honest conversations at the frontier of tech and drugs.

Powerful story telling here! Cartoons can also be used for serious stuff!

Navigating the AI’s Regulatory Maze in Pharma; Marília Aires Aires from Kiin AI Shares Insights ⚖️💊 - Tech and Drugs - Podcast - Season 1 Episode 6 is now LIVE! ... ... ... In this episode, we dive into the legal frontier of AI in healthcare with Marilia Aires, legal counsel and data protection officer at Kiin AI. With 16+ years of experience across global legal landscapes, Marilia is at the intersection of law, data ethics, and biotech, helping organizations navigate the legal and ethical minefield of AI-driven drug discovery. We explore: ✅ Who owns the data? Understanding data privacy, IP, and regulatory frameworks ✅ GDPR, AI Act & Pharma: How Europe’s AI laws impact biotech innovation ✅ The challenge of high-risk AI models in drug R&D and how companies navigate regulations ✅ Data contracts & AI governance: Ensuring compliance while fueling innovation ✅ Future trends in biotech AI: Personalized medicine, real-world data, and global data governance With AI reshaping everything in life sciences, from clinical trials to personalized treatments, Marilia breaks down the biggest legal and ethical questions companies must answer before deploying AI solutions. 💬 What’s your take on AI regulation in pharma? Are current laws helping or hindering innovation? Drop your thoughts in the comments! 📌 Prefer video? Watch on https://lnkd.in/ePk3MH4u 📌 On the go? Listen on Spotify: https://lnkd.in/eGcyJZN6 or Apple Podcasts: https://lnkd.in/evTX75SA

📅 Mark your calendar! - Tech and Drugs - Podcast - Season 1 Episode 6 drops on Thursday March 20, 2025, at 10:00 CET - Join our guest, Marília Aires from Kiin AI ... but here is a little teaser for today 🤩 The theme: AI, Data Ethics & The Legal Challenges in Drug Discovery In this episode, we will dive into the legal frontier of AI in healthcare & Life sciences with Marília Aires, legal counsel and data protection officer at Kiin AI. With 16+ years of experience across global legal landscapes, Marilia is at the intersection of law, data ethics, and biotech, helping organizations navigate the legal and ethical minefield of AI-driven drug discovery. We explore: ✅ Who owns the data? Understanding data privacy, IP, and regulatory frameworks ✅ GDPR, AI Act & Pharma: How Europe’s AI laws impact biotech innovation ✅ The challenge of high-risk AI models in drug R&D and how companies navigate regulations ✅ Data contracts & AI governance: Ensuring compliance while fueling innovation ✅ Future trends in biotech AI: Personalized medicine, real-world data, and global data governance With AI reshaping everything in life sciences, from clinical trials to personalized treatments, Marilia breaks down the biggest legal and ethical questions companies must answer before deploying AI solutions. 💬 What’s your take on AI regulation in pharma? Are current laws helping or hindering innovation? Drop your thoughts in the comments!

Tonight we are recording Tech and Drugs - Podcast episode 10! 📌 5 episodes have already been published (link below) 📌 1 edited will be released next week 📌 3 more recorded and waiting to be edited 😱 📌 1 episode will be recorded in 10 min! What a journey, and more importantly how exciting to meet and learn from all the wonderful guests 🤩 You can follow us on: YouTube: https://lnkd.in/e3wJ9nAj Spotify: https://lnkd.in/e2XXHinD Apple Podcast: https://lnkd.in/gU49CRvP

Here it is 🎙 “Tech and Drugs - Podcast” Episode #5 with 🤖💊 Nicolas Maignan is now live! The theme for today: Rethinking Drug Discovery Through AI & Polypharmacology In this episode of Tech and Drugs, I sit down with Nicolas Maignan, the AI expert and COO at Kantify, who’s redefining drug discovery with a fresh, data-driven perspective. With a background in industrial engineering and over seven years of hands-on experience in machine learning, Nicolas shares his journey from consultancy to revolutionizing R&D in healthcare—challenging the outdated one-drug, one-target dogma and championing a polypharmacological approach. We cover: ✅ How Nicolas transitioned from industrial engineering to AI-powered drug discovery ✅ The limitations of the one-drug, one-target paradigm and why it’s time for a change ✅ The promise of polypharmacology: targeting multiple pathways for more effective treatments ✅ Overcoming R&D challenges with big data and heterogeneous datasets ✅ Future trends in pharma, including the rise of AI-first companies in tackling rare diseases Whether you’re a tech enthusiast, a life sciences professional, or just curious about the future of drug discovery, this conversation is packed with insights to inspire and inform. 📌 Prefer video? Watch on YouTube: https://lnkd.in/eivGA9fB 📌 On the go? Listen on Spotify: https://lnkd.in/eccnT5fG or Apple Podcasts: https://lnkd.in/eH57TfpG 💬 What are your thoughts on shifting from single-target to multi-target drug development? Drop your views in the comments!

📅 Mark your calendar! - Tech and Drugs - Podcast - Season 1 Episode 5 drops on Tuesday March 04, 2025, at 11:30 CET - Join our guest, 🧬🎙️Nicolas Maignan from Kantify to Rethink Drug Discovery Through AI & Polypharmacology

📅 Mark your calendar! - Tech and Drugs - Podcast - Season 1 Episode 5 drops on Tuesday March 04, 2025, at 11:30 CET - Join our guest, 🧬🎙️Nicolas Maignan from Kantify to Rethink Drug Discovery Through AI & Polypharmacology Here is a teaser of what you'll learn in the next episode! In this episode of Tech and Drugs, I sit down with Nicolas Maignan, the AI expert and COO at Kantify, who’s redefining drug discovery with a fresh, data-driven perspective. With a background in industrial engineering and over seven years of hands-on experience in machine learning, Nicolas shares his journey from consultancy to revolutionizing R&D in healthcare, challenging the outdated one-drug, one-target dogma and championing a polypharmacological approach. We cover: ✅ How Nicolas transitioned from industrial engineering to AI-powered drug discovery ✅ The limitations of the one-drug, one-target paradigm and why it’s time for a change ✅ The promise of polypharmacology: targeting multiple pathways for more effective treatments ✅ Overcoming R&D challenges with big data and heterogeneous datasets ✅ Future trends in pharma, including the rise of AI-first companies in tackling rare diseases Whether you’re a tech enthusiast, a life sciences professional, or just curious about the future of drug discovery, this conversation is packed with insights to inspire and inform. 💬 What are your thoughts on shifting from single-target to multi-target drug development? Drop your views in the comments!